14 January 2009-The Institute of Clinical Research (ICR) is teaming up with the European Medical Writers Association (EMWA) in the New Year for their second joint symposium.
The seminar, entitled: Writing Protocols-collaboration and compromise or conflict and confusion?, takes place on 24 February at Novotel London Paddington and will bring together professionals involved in protocol writing, providing a forum to discuss and debate different points of view.
The day-long symposium will feature a series of thought-provoking presentations led by industry professionals and will close with a panel discussion and question and answer session. The programme is split into a morning and afternoon session, chaired by freelance medical writer Wendy Kingdom and Adam Jacobs from Dianthus Medical Limited.
Dr John Hooper, chief executive of ICR, commented: “This is our second joint symposium with EMWA following the highly-successful inaugural event in 2008.
“We are expecting that our diverse range of presenters and panellists representing the different areas of clinical research from medical writing and project management to ethics committees and investigative sites will spark fascinating debates and discussions.”
Several presentations will take place throughout the day covering topics such as the trials and tribulations of recruiting patients and the details and diplomacy of medical writing for protocols.
A month after the joint ICR and EMWA symposium will see the ICR hold its 30th anniversary Spring Conference and Exhibition. Taking place at the ICC in Birmingham on 17th and 18th March the conference will focus on Essential Updates and Lively Debates.
For further information about the symposium and to register as a delegate, please log onto the website at www.icr-global.org/community.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.